A Phase II Study of Intravitreal KIO-301 in Patients with Late-stage Retinitis Pigmentosa (ABACUS-2)

Kiora Pharmaceuticals

Status and phase: Not yet enrolling; Phase 2

Conditions: Retinitis Pigmentosa

Treatments: Drug: 100 μg KIO-301; Other: Placebo (Sterile Saline); Drug: 50 μg KIO-301

Study type: Interventional

Funder types: Industry

Identifiers

NCT06628947

KIO-301-2101

Details and patient eligibility

About

The goal of the study is to investigate the safety, tolerability and efficacy of up to 3 doses of KIO-301 administered by intravitreal (IVT) injection every 6 weeks in patients with late-stage RP.

Late-stage RP patients will include those patients with No Light Perception (NLP), or Ultra-Low Vision (ULV) and Light Perception (LP).

Full description

All enrolled and randomised study participants will attend study visits every 3 weeks during treatment (12 weeks) and follow-up (12 weeks) for PK, safety & tolerability, and efficacy assessments. The Screening period may be up to 45 days. Total duration of the main study may be up to 30 weeks.

For participants who received placebo in the main study and choose to participate in the OL extension, duration of participation will be a further 24 weeks with total participation dependent upon time between completion of the main study and initiation of the OL extension.

Enrollment: 36 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Be aged 18 years or older at the time of consent.

2. Provide informed consent prior to any study procedures, as stipulated by local laws, Ethics Committee (EC) and Regulatory Authority (RA) guidelines.

3. Be willing and able to follow all study instructions, attend all study visits, and complete all study assessments.

4. Have a clinical diagnosis of non-syndromic RP, with the exception of Usher's Syndrome Type II (USH2) which is allowed.

5. Have a visual acuity at Screening of:

   • NLP OU confirmed by inability to see pen torch light at 30cm in each eye (OU) (assigned logMAR of 4.0 as per the Berkeley Rudimentary Vision Test (BRVT).
   • LP or ULV OU limited to logMAR > 1.6 and < 4.0 as determined by the BRVT.

6. Other than intravitreal corticosteroids, participants must not receive intravitreal concomitant medications from Screening until end of study.

7. Must fail at least one functional vision Multi-luminance Orientation and Mobility (MLOM) assessment at a light level between 100 and 980 lux at Screening.

8. Must agree to follow appropriate contraception requirements from Screening until 3 months after the last dose of IMP.

   • Participants assigned female at birth who are of child-bearing potential (OCBP) must agree to a pregnancy test at Visit 1 and use an acceptable method of birth control including oral, transdermal, injectable, or implantable hormonal contraception, intrauterine device, abstinence from intercourse with partner assigned male at birth, or surgical sterilisation of partner assigned male at birth. Participants assigned female at birth are not OCBP if they have had a hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or are post-menopausal by at least 12 months.
   • Participants assigned male at birth with a partner OCBP must be surgically sterile for at least 3 months prior to starting study drug, or ensure their partner uses contraception as outlined above, and must use a male condom. Participants assigned male at birth must not donate sperm from Screening until 3 months after the last dose of IMP.
   • Participants who have practiced true abstinence for at least 1 year due to usual and preferred lifestyle choice are exempt from contraceptive requirements. If a participant who is abstinent becomes sexually active, they must agree to use appropriate contraception as described above.

Exclusion criteria

1. Pregnant or breast-feeding, or plan to become pregnant during the study.
2. Have evidence of material/substantial optic nerve disease.
3. Have a history of one or more retinal detachments.
4. Other than RP related macular pathologies, have clinically significant ocular disease (e.g., corneal oedema, uveitis, severe keratoconjunctivitis sicca), or clinically significant opacities of the media which might interfere with the study assessments, or the ability of the participant to complete the study.
5. Have a history of high myopia (at least > 6 diopters)
6. Have uncontrolled severe glaucoma defined as intraocular pressure (IOP) of >26 mmHg when on 2 or more IOP lowering medications and cup disc ratio of >0.8, as diagnosed by an ophthalmologist.
7. Have had a previous intraocular surgery (excluding phacoemulsification cataract surgery and YAG capsulotomy more than 12 months prior to first study drug administration)
8. Have aphakia or a subluxed intraocular lens, or have evidence of zonular weakness that in the opinion of the investigator would result in light obfuscation.
9. Have a psychiatric condition that, in the investigator's opinion, precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder; disorder requiring lithium; or within five years prior to screening, a history of suicide plan.
10. Have any clinically significant abnormality at screening determined by medical history, vital signs, clinical biochemistry, haematology, urinalysis, or a 12-lead electrocardiogram (ECG), as assessed by the investigator, which might interfere with the study assessments or the ability of the participant to complete the study.
11. Have any other medical condition or significant co-morbidities, or any finding during screening, which in the view of the Investigator is likely to interfere with the study or put the Participant at risk, confound study data, or interfere significantly with study participation.
12. Have clinical signs of active ocular or systemic infection and/or a temperature greater than 38.0°C at the time of screening. Study entry must be deferred at least 14 days from resolution.
13. Have participated in any investigational study within 30 days prior to screening, prior exposure to an investigational product within 5 elimination half-lives, or planned used of an investigational product or device during the study.
14. Have known or suspected hypersensitivity to any of the study drug excipients.
15. Are taking any medications that are known to be toxic to the retina or optic nerve.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

36 participants in 2 patient groups

50 μg KIO-301

Experimental group

Description:

50 μg KIO-301 or placebo administered by IVT injection bilaterally (OU) once every 6 weeks for 3 administrations per participant.

Treatment:

Drug: 50 μg KIO-301

Other: Placebo (Sterile Saline)

100 μg KIO-301

Experimental group

Description:

100 μg KIO-301 or placebo administered by IVT injection OU once every 6 weeks for 3 administrations per participant.

Treatment:

Other: Placebo (Sterile Saline)

Drug: 100 μg KIO-301